---
title: Emerging immunotherapies in the Hodgkin Lymphoma Armamentarium
date: '2024-04-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38676917/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240428181057&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'INTRODUCTION: Brentuximab vedotin and the PD-1 inhibitors have improved
  outcomes for classic Hodgkin lymphoma (cHL), but better therapies are needed for
  patients who relapse after these agents. Based on improved understanding of cHL
  biology, there is a robust pipeline of novel therapies in development. In this review,
  we highlight emerging immunotherapeutic agents and combinations for ...'
disable_comments: true
---
INTRODUCTION: Brentuximab vedotin and the PD-1 inhibitors have improved outcomes for classic Hodgkin lymphoma (cHL), but better therapies are needed for patients who relapse after these agents. Based on improved understanding of cHL biology, there is a robust pipeline of novel therapies in development. In this review, we highlight emerging immunotherapeutic agents and combinations for ...